| Name | Title | Contact Details |
|---|---|---|
Elizabeth Kerns |
Senior Vice President - Chief Information Officer - Chief Security Officer | Profile |
Mary Ford |
Chief Information Officer | Profile |
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
PL Developments is a Westbury, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carolina Clinical Research is a Belews Creek, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Channel 10 Klvx is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OHCOW is a Windsor, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.